Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Milk who wrote (291)	6/24/1998 11:49:00 AM
From: Milk	Read Replies (2) \| Respond to of 369

Wednesday June 24, 9:18 am Eastern Time UroMed seeks radioactive seed clearance NEEDHAM, Mass., June 24 (Reuters) - UroMed Corp. said Wednesday that it has submitted a premarket notification 510(k) application to the U.S. Food and Drug Administration for market clearance for its radioactive seeds to be used to treat prostate cancer. UroMed said its goal is to market the seeds in the first quarter of next year. The company noted that review times at the FDA are currently estimated to average 90 days for premarket notifications. The 510(k) application is used when there exist similar, previously-approved technologies in the marketplace. --------------------------------------------------------------------------------